Search results for "PHARMACOPHORE"

showing 10 items of 71 documents

Evaluating the stability of pharmacophore features using molecular dynamics simulations.

2016

Abstract Molecular dynamics simulations of twelve protein—ligand systems were used to derive a single, structure based pharmacophore model for each system. These merged models combine the information from the initial experimental structure and from all snapshots saved during the simulation. We compared the merged pharmacophore models with the corresponding PDB pharmacophore models, i.e., the static models generated from an experimental structure in the usual manner. The frequency of individual features, of feature types and the occurrence of features not present in the static model derived from the experimental structure were analyzed. We observed both pharmacophore features not visible in …

0301 basic medicineProtein FlexibilityProtein ConformationBiophysicsStability (learning theory)Molecular Dynamics SimulationLigands01 natural sciencesBiochemistryLigandScoutSet (abstract data type)03 medical and health sciencesMolecular dynamicsComputational chemistryFeature (machine learning)Pharmacophore ModelingSensitivity (control systems)Molecular BiologyBinding Sites010405 organic chemistryChemistryStructure-based Pharmacophore ModelingMolecular DynamicProteinsHydrogen BondingCell Biology0104 chemical sciences030104 developmental biologyRankingModels ChemicalDrug DesignPharmacophoreBiological systemProtein BindingBiochemical and biophysical research communications
researchProduct

Reverse screening on indicaxanthin from Opuntia ficus-indica as natural chemoactive and chemopreventive agent

2018

Indicaxanthin is a bioactive and bioavailable betalain pigment extracted from Opuntia ficus indica fruits. Indicaxanthin has pharmacokinetic proprieties, rarely found in other phytochemicals, and it has been demonstrated that it provides a broad-spectrum of pharmaceutical activity, exerting anti-proliferative, anti-inflammatory, and neuromodulator effects. The discovery of the Indicaxanthin physiological targets plays an important role in understanding the biochemical mechanism. In this study, combined reverse pharmacophore mapping, reverse docking, and text-based database search identified Inositol Trisphosphate 3-Kinase (ITP3K-A), Glutamate carboxypeptidase II (GCPII), Leukotriene-A4 hydr…

0301 basic medicineStatistics and ProbabilityMolecular dynamicPyridinesKainate receptorIndicaxanthinPhytochemical01 natural sciencesGeneral Biochemistry Genetics and Molecular BiologyDocking03 medical and health scienceschemistry.chemical_compoundNeoplasmsGlutamate carboxypeptidase IIData MiningHumansEnzyme InhibitorsMM-GBSAPharmacophore modelingBinding SitesGeneral Immunology and MicrobiologyReverse screening010405 organic chemistryAnti-cancerApplied MathematicsPhosphodiesteraseOpuntiaPhosphoserine phosphataseInositol trisphosphateGeneral MedicineAntineoplastic Agents Phytogenic0104 chemical sciencesBetaxanthinsNeoplasm ProteinsNeuromodulatorMolecular Docking SimulationAnti-inflammatory agent030104 developmental biologychemistryBiochemistryDocking (molecular)Modeling and SimulationPharmacophoreGeneral Agricultural and Biological SciencesIndicaxanthin
researchProduct

Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants

2021

Abstract Background COVID-19, declared a pandemic in March 2020 by the World Health Organization is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The virus has already killed more than 2.3 million people worldwide. Object The principal intent of this work was to investigate lead compounds by screening natural product library (NPASS) for possible treatment of COVID-19. Methods Pharmacophore features were used to screen a large database to get a small dataset for structure-based virtual screening of natural product compounds. In the structure-based screening, molecular docking was performed to find a potent inhibitor molecule against the main protease (Mpro) of SARS-…

0301 basic medicineStereochemistrymedicine.medical_treatmentPhytochemicalsProtein Data Bank (RCSB PDB)Health Informaticsmedicine.disease_causeMolecular Docking SimulationAntiviral AgentsArticleDocking03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansProtease InhibitorsCoronavirusVirtual screeningNatural productsProteaseChemistrySARS-CoV-2COVID-19Computer Science ApplicationsProteaseCoronavirusMolecular Docking Simulation030104 developmental biologyDocking (molecular)PharmacophoreLead compound030217 neurology & neurosurgeryMproPeptide HydrolasesComputers in Biology and Medicine
researchProduct

Repurposing old drugs to fight multidrug resistant cancers.

2020

Overcoming multidrug resistance represents a major challenge for cancer treatment. In the search for new chemotherapeutics to treat malignant diseases, drug repurposing gained a tremendous interest during the past years. Repositioning candidates have often emerged through several stages of clinical drug development, and may even be marketed, thus attracting the attention and interest of pharmaceutical companies as well as regulatory agencies. Typically, drug repositioning has been serendipitous, using undesired side effects of small molecule drugs to exploit new disease indications. As bioinformatics gain increasing popularity as an integral component of drug discovery, more rational approa…

0301 basic medicineVirtual screeningCancer ResearchDrug repurposingSettore BIO/11 - Biologia MolecolareAntineoplastic AgentsDrug resistanceBioinformatics03 medical and health sciencesClinical cancer trials; Drug repurposing; Multidrug resistant cancer; Pharmacophore modelling; Virtual screening0302 clinical medicineNeoplasmsDrug DiscoveryMedicineHumansPharmacology (medical)Computer SimulationRepurposingPharmacologyVirtual screeningDrug discoverybusiness.industryDrug RepositioningComputational BiologyDrug Resistance Multiple3. Good healthMultiple drug resistanceDrug repositioning030104 developmental biologyInfectious DiseasesOncologyDrug developmentDrug Resistance Neoplasm030220 oncology & carcinogenesisMultidrug resistant cancerPharmacophore modellingPharmacophorebusinessClinical cancer trialsDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
researchProduct

2019

Golgi α-mannosidase II (GMII) is a glycoside hydrolase playing a crucial role in the N-glycosylation pathway. In various tumour cell lines, the distribution of N-linked sugars on the cell surface is modified and correlates with the progression of tumour metastasis. GMII therefore is a possible molecular target for anticancer agents. Here, we describe the identification of a non-competitive GMII inhibitor using computer-aided drug design methods including identification of a possible allosteric binding site, pharmacophore search and virtual screening.

0301 basic medicineVirtual screeningMultidisciplinaryChemistryCellAllosteric regulationGolgi apparatus010402 general chemistry01 natural sciencesEnzyme structure0104 chemical sciences03 medical and health sciencessymbols.namesake030104 developmental biologymedicine.anatomical_structureBiochemistrymedicinesymbolsGlycoside hydrolaseBinding sitePharmacophorePLOS ONE
researchProduct

Binding mode analysis of ABCA7 for the prediction of novel Alzheimer's disease therapeutics

2021

Graphical abstract

ATP Adenosine-triphosphateNBD nucleotide binding domainGSH reduced glutathionePolypharmacologyAlzheimer’s disease (AD)ATP-binding cassette transporterHTS high-throughput screeningBiochemistryABCA7Structural BiologyPLIF protein ligand interactionMSD membrane spanning domainPDB protein data bankTM transmembrane helixABC ATP-binding cassetteMultitarget modulation (PANABC)RMSD root mean square distanceABC transporter (ABCA1 ABCA4 ABCA7)Computer Science ApplicationsMOE Molecular Operating EnvironmentPharmacophoreSNP single-nucleotide polymorphismBiotechnologyResearch ArticleBBB blood-brain barrierBiophysicsDrug designComputational biologyBiologyAD Alzheimer’s diseasePET positron emission tomographyIC intracellular helixAPP amyloid precursor proteincryo-EM cryogenic-electron microscopyGeneticsHomology modelingBinding siteRational drug design and developmentComputingMethodologies_COMPUTERGRAPHICSNBD-cholesterol 7-nitro-2-13-benzoxadiazol-4-yl-cholesterolTransporterPSO particle swarm optimizationPET tracer (PETABC)ECD extracellular domainR-domain/region regulatory domain/regionABCA1biology.proteinEH extracellular helixTP248.13-248.65BODIPY-cholesterol 44-difluoro-4-bora-3a4a-diaza-s-indacene-cholesterolComputational and Structural Biotechnology Journal
researchProduct

Synthesis and Characterization of a Novel Series of Agonist Compounds as Potential Radiopharmaceuticals for Imaging Dopamine D-2/3 Receptors in Their…

2014

Imaging of dopamine D2/3 receptors (D2/3R) can shed light on the nature of several neuropsychiatric disorders in which dysregulation of D2/3R signaling is involved. Agonist D2/3 tracers for PET/SPECT imaging are considered to be superior to antagonists because they are more sensitive to dopamine concentrations and may selectively label the high-affinity receptor state. Carbon-11-labeled D2/3R agonists have been developed, but these short-lived tracers can be used only in centers with a cyclotron. Here, we report the development of a series of novel D2R agonist compounds based on the 2-aminomethylchromane (AMC) scaffold that provides ample opportunities for the introduction of longer-lived […

AgonistD-3 RECEPTORPHARMACOPHOREChemistrymedicine.drug_classDERIVATIVESPharmacologyIN-VIVO ACTIVITYHUMAN BRAINRadioligand AssayANTERIOR-PITUITARYPOSITRON-EMISSION-TOMOGRAPHYENDOGENOUS DOPAMINEIn vivoDopamineSpect imagingDopamine receptor D2Drug DiscoveryLIGAND-BINDINGmedicineMolecular MedicineReceptorAGENTSEndogenous agonistmedicine.drugJournal of Medicinal Chemistry
researchProduct

Synthesis and biological activities of a new class of heat shock protein 90 inhibitors, designed by energy-based pharmacophore virtual screening

2013

The design through energy-based pharmacophore virtual screening has led to aminocyanopyridine derivatives as efficacious new inhibitors of Hsp90. The synthesized compounds showed a good affinity for the Hsp90 ATP binding site in the competitive binding assay. Moreover, they showed an excellent antiproliferative activity against a large number of human tumor cell lines. Further biological studies on the derivative with the higher EC50 confirmed its specific influence on the cellular pathways involving Hsp90.

AminopyridinesInhibitory Concentration 50Structure-Activity RelationshipUser-Computer InterfaceHeat shock proteinCell Line TumorSettore BIO/10 - BiochimicaDrug DiscoveryHumansHSP90 Heat-Shock ProteinsBinding siteVirtual screeningheat shock protein 90 inhibitors energy-based pharmacophore virtual screening cell cycle antiproliferative activitybiologyChemistryHsp90Combinatorial chemistrySettore CHIM/08 - Chimica FarmaceuticaHuman tumorMolecular Docking SimulationCell cultureDrug DesignEnergy basedbiology.proteinMolecular MedicinePharmacophoreDrug Screening Assays Antitumor
researchProduct

Pharmacophore modeling e screening in silico di nuovi inibitori della proteina antiapoptotica Bcl-xl

2008

Bcl-xlpharmacophore modelingin silico screeningapoptosiSettore CHIM/08 - Chimica Farmaceutica
researchProduct

Insect-associated bacteria assemble the antifungal butenolide gladiofungin by non-canonical polyketide chain termination

2020

Abstract Genome mining of one of the protective symbionts (Burkholderia gladioli) of the invasive beetle Lagria villosa revealed a cryptic gene cluster that codes for the biosynthesis of a novel antifungal polyketide with a glutarimide pharmacophore. Targeted gene inactivation, metabolic profiling, and bioassays led to the discovery of the gladiofungins as previously‐overlooked components of the antimicrobial armory of the beetle symbiont, which are highly active against the entomopathogenic fungus Purpureocillium lilacinum. By mutational analyses, isotope labeling, and computational analyses of the modular polyketide synthase, we found that the rare butenolide moiety of gladiofungins deriv…

Burkholderia gladioliAntifungal AgentsBurkholderianatural productsantifungal compoundsMicrobial Sensitivity TestsBiosynthesis010402 general chemistry01 natural sciencesCatalysisPurpureocillium lilacinumPolyketide4-ButyrolactonePolyketide synthasegenome miningGene clusterAnimalsButenolidebiology010405 organic chemistryCommunicationGeneral Chemistrybiology.organism_classificationCommunications0104 chemical sciencesColeopteraBiochemistryPolyketidesHypocrealesbiology.proteinLactimidomycinPharmacophore
researchProduct